Muscular Dystrophy UK Funds New Research at Cardiff University for a Rare Muscle Condition

Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on a news report from Herald.Wales (see sources below). Published: October 11, 2026.



Rare muscle conditions often have no treatment at all, partly because they affect so few people that research money rarely flows towards them. That is why news of new funding matters, even when it comes from far away. In September 2026, the UK charity Muscular Dystrophy UK announced that it is investing £1.5 million in ten new research projects across England, Scotland and Wales. One of them, at Cardiff University, focuses on a rare condition called ADSS1 myopathy. This article explains the news in simple words and what it means for patients around the world, including in Pakistan.

Quick facts

  • Muscular Dystrophy UK announced £1.5 million for ten new research projects in England, Scotland and Wales.
  • One project at Cardiff University is a four-year PhD led by Dr Fabrizio Pertusati, a lecturer in medicinal chemistry.
  • It targets ADSS1 myopathy, a rare muscle condition for which there is currently no available treatment.
  • The charity now supports 56 active projects across more than 25 conditions, with a total research commitment of over £10 million.
  • The announcement came during Muscular Dystrophy Awareness Month, observed in September.

What Was Announced?

Muscular Dystrophy UK is the leading charity for people living with muscle-wasting conditions in the United Kingdom. It supports more than 110,000 children and adults living with one of over 60 such conditions. The new £1.5 million investment funds ten projects at universities across the UK, including in Cardiff, Glasgow, London, Newcastle and Nottingham. A key aim of the charity's ten-year strategy is to widen its research portfolio and speed up the development of new treatments.

The Cardiff Project

The Cardiff University project is funded as a four-year PhD studentship. Dr Fabrizio Pertusati and a PhD student will continue work that began with an earlier charity-funded study, which found a possible way to restore a key molecule that is missing in people with ADSS1 myopathy.

ADSS1 myopathy, also written ADSSL1 myopathy, is a rare inherited muscle condition. At present there is no treatment for it. A promising therapy is expected to enter an early-stage clinical trial soon, but it is difficult to deliver and may place a heavy burden on patients. The new study aims to develop a version of the treatment that reaches the muscles more effectively. If it succeeds, it could improve quality of life for people with ADSS1 myopathy and increase the chance that the treatment becomes widely available. The researchers and the charity also say it might help improve treatments for other rare muscle conditions in the future.



Why This Matters Beyond the UK

  • Rare does not mean ignored. Funding aimed at very rare conditions shows that research is moving beyond the best-known types such as Duchenne.
  • One discovery can help many. Methods developed for one rare condition, especially ways of delivering treatment to muscle, can later help other muscle diseases.
  • Training the next generation. A PhD studentship builds new scientists who will keep working on neuromuscular disease for years to come.
  • Research needs patients to be counted. Clinical trials can only start where patients are known and diagnosed.

What It Means for Families in Pakistan

Most of this research takes place in other countries, and treatments that come out of it will take years to arrive, if at all, in Pakistan. But there are things we can do now. Families with rare muscle conditions can get an exact genetic diagnosis, because many future trials will only enrol patients with a confirmed gene change. Patients can also register with a national or international registry. Registration does not promise access to any treatment, but it makes patients visible to researchers and doctors, and it supports the case for better diagnosis and care in Pakistan.

It is also a good reminder that September is awareness month for muscular dystrophy worldwide. Muscular Dystrophy Pakistan observes LGMD Awareness Day every year on 30 September.

Muscular Dystrophy Pakistan
Every patient counts. Register with MDP.
Patients and families living with muscular dystrophy and other neuromuscular disorders can register on the MDP patient registration portal. Your registration helps us understand the real picture and speak up for timely diagnosis, care and support.
✔ Simple online registration
✔ For patients and families
✔ Helps make every patient visible
Register Now →
musculardystrophypk.org/registration

Frequently Asked Questions

What is ADSS1 myopathy?

It is a rare inherited muscle condition. At present there is no available treatment, which is why research into it matters.

Is a treatment available now?

No. A therapy is expected to enter an early-stage clinical trial, and the Cardiff project aims to make a more effective version of it. These are early steps.

Can patients in Pakistan join these studies?

Not directly at present. Trials usually enrol patients in the countries where they are run. A confirmed genetic diagnosis and registration with a registry are the best preparation for the future.

Small Steps That Lead to Big Changes

Every treatment we have today began as a small research project. News like this shows that researchers and charities around the world are working on muscle conditions that were once ignored. Follow the MDP blog for more research updates, and share this article with someone who may find hope in it.

Sources and Further Reading

Medical disclaimer: This article is for awareness and education only. It is not a substitute for professional medical advice, diagnosis or treatment. Please consult a qualified doctor about any medical concern.

Comments

Post a Comment

Popular posts from this blog

Muscular Dystrophy: Complete Guide to Causes, Symptoms, Types and Treatment

Image
  Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on information from NINDS, NICHD and MDA (see sources below). Last updated: October 3, 2026. Muscular dystrophy is a group of inherited genetic conditions that cause muscles to become weaker over time. For many families in Pakistan, the name is heard for the first time only after a child has been falling often, walking late or struggling to climb stairs, sometimes after years of visits to different doctors. This guide explains muscular dystrophy in simple words: what it is, why it happens, its main types, how it is diagnosed, what care is available, and where families in Pakistan can find support. Quick facts Muscular dystrophy (MD) is a group of more than 30 genetic diseases. It causes progressive muscle weakness: muscles get weaker over time. It is not contagious and is not caused by anything parents did. Most types have no complete cure yet, but proper medical care and monitoring make a real difference. E...
Read more

Genetics of Muscular Dystrophy: How It Is Inherited (X-Linked, Autosomal)

Image
Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on information from NINDS, MedlinePlus Genetics and Parent Project Muscular Dystrophy (see sources below). Last updated: October 5, 2026. "Why did this happen to our child?" "Will my other children be affected?" "Can my sister be a carrier?" These are the questions families ask first after a muscular dystrophy diagnosis, and the answers lie in genetics. This guide explains in simple words how muscular dystrophy is inherited, what X-linked and autosomal inheritance mean, what the chances are for a family, and why genetic testing and counselling matter, especially in Pakistan. Quick facts Muscular dystrophies are caused by changes (mutations) in genes that give instructions for making muscle proteins. Duchenne and Becker muscular dystrophy are caused by changes in the DMD gene , which is located on the X chromosome. They are inherited in an X-linked recessive pattern. Many other ...
Read more

Duchenne Muscular Dystrophy Survival Has Risen from 19 to 29 Years: What the New Analysis Means

Image
Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on a study published in the Journal of Neurology (2026) and a news report on it (see sources below). Published: October 11, 2026. For decades, families facing a Duchenne muscular dystrophy diagnosis were given a heavy number: most boys would not live beyond their late teens or early twenties. A new analysis published in the Journal of Neurology in October 2026 shows how much that picture has changed. By combining the results of dozens of studies, researchers found that median survival in Duchenne has climbed from about 19 years to nearly 29 years, and the study points to the reasons: better breathing support at home and better heart care. This article explains what the study found, what it does not tell us, and what it means for families in Pakistan. Quick facts The study was led by researchers at University Hospital Zurich and combined 53 earlier studies with more than 13,000 patients. In groups that includ...
Read more